| Year |
Citation |
Score |
| 2020 |
Luban J, Sattler R, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, ... ... Welch EM, et al. The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Virus Research. 198246. PMID 33249060 DOI: 10.1016/j.virusres.2020.198246 |
0.643 |
|
| 2020 |
Luban J, Sattler R, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, ... ... Welch EM, et al. The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Biorxiv : the Preprint Server For Biology. PMID 32793904 DOI: 10.1101/2020.08.05.238394 |
0.643 |
|
| 2020 |
Baiazitov RY, Friesen W, Johnson B, Mollin A, Sheedy J, Sierra J, Weetall M, Branstrom A, Welch E, Moon YC. Chemical modifications of G418 (geneticin): Synthesis of novel readthrough aminoglycosides results in an improved in vitro safety window but no improvements in vivo. Carbohydrate Research. 495: 108058. PMID 32658832 DOI: 10.1016/J.Carres.2020.108058 |
0.359 |
|
| 2019 |
Kramerova I, Kumagai-Cresse C, Ermolova N, Mokhonova E, Marinov M, Capote J, Becerra D, Quattrocelli M, Crosbie RH, Welch E, McNally EM, Spencer MJ. Spp1 (osteopontin) promotes TGFβ processing in fibroblasts of dystrophin deficient muscles through matrix metalloproteinases. Human Molecular Genetics. PMID 31411676 DOI: 10.1093/Hmg/Ddz181 |
0.354 |
|
| 2018 |
Ng MY, Zhang H, Weil A, Singh V, Jamiolkowski R, Baradaran-Heravi A, Roberge M, Jacobson A, Friesen W, Welch E, Goldman YE, Cooperman BS. New Assay Measuring Direct Interaction of Nonsense Suppressors with the Eukaryotic Protein Synthesis Machinery. Acs Medicinal Chemistry Letters. 9: 1285-1291. PMID 30613341 DOI: 10.1021/Acsmedchemlett.8B00472 |
0.568 |
|
| 2018 |
Friesen WJ, Johnson B, Sierra J, Zhuo J, Vazirani P, Xue X, Tomizawa Y, Baiazitov R, Morrill C, Ren H, Babu S, Moon YC, Branstrom A, Mollin A, Hedrick J, ... ... Welch EM, et al. The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential. Plos One. 13: e0206158. PMID 30359426 DOI: 10.1371/Journal.Pone.0206158 |
0.56 |
|
| 2017 |
Friesen WJ, Trotta CR, Tomizawa Y, Zhuo J, Johnson B, Sierra J, Roy B, Weetall M, Hedrick J, Sheedy J, Takasugi J, Moon YC, Babu S, Baiazitov R, Leszyk JD, ... ... Welch EM, et al. The nucleoside analog clitocine is a potent and efficacious readthrough agent. Rna (New York, N.Y.). PMID 28096517 DOI: 10.1261/Rna.060236.116 |
0.606 |
|
| 2016 |
Roy B, Friesen WJ, Tomizawa Y, Leszyk JD, Zhuo J, Johnson B, Dakka J, Trotta CR, Xue X, Mutyam V, Keeling KM, Mobley JA, Rowe SM, Bedwell DM, Welch EM, et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proceedings of the National Academy of Sciences of the United States of America. PMID 27702906 DOI: 10.1073/Pnas.1605336113 |
0.613 |
|
| 2016 |
Moosajee M, Tracey-White D, Smart M, Weetall M, Torriano S, Kalatzis V, da Cruz L, Coffey P, Webster AR, Welch E. Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model. Human Molecular Genetics. PMID 27329764 DOI: 10.1093/Hmg/Ddw184 |
0.408 |
|
| 2016 |
Woll MG, Qi H, Turpoff A, Zhang N, Zhang X, Chen G, Li C, Huang S, Yang T, Moon YC, Lee CS, Choi S, Almstead NG, Naryshkin NN, Dakka A, ... ... Welch E, et al. Discovery and optimization of small molecule splicing modifiers of survival motor neuron 2 (SMN2) as a treatment for spinal muscular atrophy. Journal of Medicinal Chemistry. PMID 27299569 DOI: 10.1021/Acs.Jmedchem.6B00460 |
0.366 |
|
| 2014 |
Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, Ling KK, Karp GM, Qi H, Woll MG, Chen G, Zhang N, Gabbeta V, Vazirani P, Bhattacharyya A, ... ... Welch EM, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science (New York, N.Y.). 345: 688-93. PMID 25104390 DOI: 10.1126/Science.1250127 |
0.57 |
|
| 2014 |
Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, ... ... Welch EM, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine. 2: 539-47. PMID 24836205 DOI: 10.1016/S2213-2600(14)70100-6 |
0.573 |
|
| 2013 |
Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annual Review of Medicine. 64: 407-25. PMID 23215857 DOI: 10.1146/Annurev-Med-120611-144851 |
0.7 |
|
| 2011 |
Naryshkin N, Narasimhan J, Dakka A, Gabbeta V, Haley M, Jung S, Crona J, Vazirani P, Furia B, Qi H, Woll M, Lee S, Choi S, Koyama H, Yang T, ... ... Welch E, et al. T.P.7 Small molecule compounds correct alternative splicing of the SMN2 gene and restore SMN protein expression and function Neuromuscular Disorders. 22: 848. DOI: 10.1016/J.Nmd.2012.06.153 |
0.308 |
|
| 2010 |
Wang B, Yang Z, Brisson BK, Feng H, Zhang Z, Welch EM, Peltz SW, Barton ER, Brown RH, Sweeney HL. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. Journal of Applied Physiology (Bethesda, Md. : 1985). 109: 901-5. PMID 20558759 DOI: 10.1152/Japplphysiol.01366.2009 |
0.583 |
|
| 2009 |
Peltz SW, Welch EM, Trotta CR, Davis T, Jacobson A. Targeting post-transcriptional control for drug discovery. Rna Biology. 6: 329-34. PMID 19574739 DOI: 10.4161/Rna.6.3.8953 |
0.676 |
|
| 2009 |
Peltz SW, Welch EM, Jacobson A, Trotta CR, Naryshkin N, Sweeney HL, Bedwell DM. Nonsense suppression activity of PTC124 (ataluren). Proceedings of the National Academy of Sciences of the United States of America. 106: E64; author reply E6. PMID 19506240 DOI: 10.1073/Pnas.0901936106 |
0.654 |
|
| 2009 |
Kerem E, Kerem B, Welch EM, Trotta C, Weetall M, Miller L, Jacobson A, Peltz SW. PTC124 for cystic fibrosis - Authors' reply The Lancet. 373: 1426-1427. PMID 19394530 DOI: 10.1016/S0140-6736(09)60820-5 |
0.6 |
|
| 2009 |
Bedwell D, Wang D, Shukla C, Liu X, Yeh S, Welch E, Schoeb T, Keeling K. 12. Suppression of a nonsense mutation in a mouse model of Hurler syndrome Molecular Genetics and Metabolism. 96: S14. DOI: 10.1016/J.Ymgme.2008.11.013 |
0.346 |
|
| 2008 |
Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proceedings of the National Academy of Sciences of the United States of America. 105: 2064-9. PMID 18272502 DOI: 10.1073/Pnas.0711795105 |
0.63 |
|
| 2008 |
Liu Y, Margaritis P, Khazi F, Downey H, Kadauke S, Hasbrouck N, Sheedy J, Welch E, Weetall M, High KA. Nonsense Suppression Approaches in Treating Hemophilia Blood. 112: 512-512. DOI: 10.1182/Blood.V112.11.512.512 |
0.431 |
|
| 2007 |
Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 447: 87-91. PMID 17450125 DOI: 10.1038/Nature05756 |
0.724 |
|
| 2007 |
Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. Journal of Clinical Pharmacology. 47: 430-44. PMID 17389552 DOI: 10.1177/0091270006297140 |
0.544 |
|
| 2000 |
Welch EM, Jacobson A. An internal open reading frame triggers nonsense-mediated decay of the yeast SPT10 mRNA. The Embo Journal. 18: 6134-45. PMID 10545123 DOI: 10.1093/Emboj/18.21.6134 |
0.568 |
|
| 1994 |
Peltz SW, He F, Welch E, Jacobson A. Nonsense-mediated mRNA decay in yeast. Progress in Nucleic Acid Research and Molecular Biology. 47: 271-98. PMID 8016322 DOI: 10.1016/S0079-6603(08)60254-8 |
0.661 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Zhao X, Feng Z, Ling KK, Mollin A, Sheedy J, Yeh S, Petruska J, Narasimhan J, Dakka A, Welch E, Karp G, Chen KS, Metzger F, Ratni H, Lotti F, et al. Pharmacokinetics, Pharmacodynamics and Efficacy of a Small Molecule SMN2 Splicing Modifier in Mouse Models of Spinal Muscular Atrophy. Human Molecular Genetics. PMID 26931466 DOI: 10.1093/Hmg/Ddw062 |
0.27 |
|
| 2021 |
Zhao X, Feng Z, Risher N, Mollin A, Sheedy J, Ling KKY, Narasimhan J, Dakka A, Baird JD, Ratni H, Lutz C, Chen K, Naryshkin N, Ko CP, Welch E, et al. SMN protein is required throughout life to prevent spinal muscular atrophy disease progression. Human Molecular Genetics. PMID 34368854 DOI: 10.1093/hmg/ddab220 |
0.261 |
|
| 2016 |
Feng Z, Ling KK, Zhao X, Zhou C, Karp G, Welch EM, Naryshkin N, Ratni H, Chen KS, Metzger F, Paushkin S, Weetall M, Ko CP. Pharmacologically-induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Human Molecular Genetics. PMID 26758873 DOI: 10.1093/Hmg/Ddv629 |
0.247 |
|
| 2015 |
Bedwell DM, Wang D, Welch EM, Keeling KM. The nonsense suppression drug PTC124 restored alpha-l-iduronidase activity and reduces glycosaminoglycan accumulation in MPS IH mice carrying the Idua-W402X mutation Molecular Genetics and Metabolism. 114: S20. DOI: 10.1016/J.Ymgme.2014.12.026 |
0.221 |
|
| 2023 |
Liu G, Lipari P, Mollin A, Jung S, Teplova I, Li W, Ying L, More V, Lennox W, Yeh S, McGann E, Moon YC, Rice C, Huarte E, Gruszka B, ... ... Welch E, et al. Comparison of pharmaceutical properties and biological activity of prednisolone, deflazacort, and vamorolone in DMD disease models. Human Molecular Genetics. PMID 37819629 DOI: 10.1093/hmg/ddad173 |
0.205 |
|
| 2008 |
Paushkin S, Dakka A, Khandker L, Kaushal R, Qi H, Woll M, Hedrick J, Mollin A, Moon Y, Weetall M, Welch E. G.P.4.04 PTC Therapeutics identifies compounds that modulate SMN protein expression at the post-transcriptional level Neuromuscular Disorders. 18: 761. DOI: 10.1016/j.nmd.2008.06.131 |
0.203 |
|
| 2022 |
Zaworski PG, Schwartz R, Burr J, Skutnik D, Mollin A, Kumar B, Ngumah Q, Welch E, Johnson B, Narasimhan J, Weetall M. Quantitation of Pax-6 protein in ocular impression cytology samples using an electrochemiluminescence immunoassay. Analytical Biochemistry. 656: 114876. PMID 36058293 DOI: 10.1016/j.ab.2022.114876 |
0.199 |
|
| 2007 |
Paushkin S, Volkova L, Dakka A, Patel M, Furia B, Bhattacharyya A, Welch E. G.P.2.17 An innovative and integrated approach to identify compounds that modulate SMN protein expression at the post-transcriptional level Neuromuscular Disorders. 17: 781. DOI: 10.1016/j.nmd.2007.06.073 |
0.187 |
|
| 2011 |
Naryshkin N, Narasimhan J, Dakka A, Gabbeta V, Haley M, Crona J, Jung S, Vazirani P, Furia B, Qi H, Woll M, Yang T, Lee S, Choi S, Chen G, ... ... Welch E, et al. P3.12 Small molecule compounds that correct alternative splicing of the SMN2 gene and restore SMN protein expression and function Neuromuscular Disorders. 21: 685. DOI: 10.1016/j.nmd.2011.06.906 |
0.186 |
|
| 2020 |
Kong R, Ma J, Hwang S, Moon YC, Welch EM, Weetall M, Colacino JM, Almstead N, Babiak J, Goodwin E. In vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren. Pharmacology Research & Perspectives. 8: e00576. PMID 32196986 DOI: 10.1002/prp2.576 |
0.165 |
|
| 2021 |
Ma J, Kaushik D, Yeh S, Northcutt V, Babiak J, Risher N, Weetall M, Moon YC, Welch EM, Molony L, O'Keefe K, Kong R. In Vitro Metabolism, Pharmacokinetics and Drug Interaction Potentials of Emvododstat, a DHODH Inhibitor. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-42. PMID 34846990 DOI: 10.1080/00498254.2021.2010287 |
0.162 |
|
| 2015 |
Naryshkin N, Dakka A, Gabbeta V, Pichardo J, Vazirani P, Ryan G, Woll M, Turpoff A, Zhang N, Zhang S, Karp G, Welch E. Small molecule compounds that promote exon skipping in the DMD gene Neuromuscular Disorders. 25: S261. DOI: 10.1016/j.nmd.2015.06.275 |
0.157 |
|
| 2020 |
Feng Z, Ling KKY, Zhao X, Zhou C, Karp G, Welch EM, Naryshkin N, Ratni H, Chen KS, Metzger F, Paushkin S, Weetall M, Ko CP. Corrigendum to: Pharmacologically-induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Human Molecular Genetics. PMID 33201218 DOI: 10.1093/hmg/ddaa247 |
0.123 |
|
| 2007 |
Friesen W, Tomizawa Y, Zhuo J, Baiazitov R, Lee S, Nadarajan T, Moon Y, Sweeney H, Welch E. G.P.3.06 Identification and characterization of small molecules for the treatment of Duchenne muscular dystrophy Neuromuscular Disorders. 17: 783-784. DOI: 10.1016/j.nmd.2007.06.081 |
0.11 |
|
| 2008 |
Welch E, Goetz D, Almstead N. Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt. Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology / Edited by the Gaetano Conte Academy For the Study of Striated Muscle Diseases. 27: 63-8. PMID 19364064 |
0.106 |
|
| 2008 |
Friesen W, Acharjee S, Zhuo J, Baiazitov R, Lee S, Moon Y, Sweeney H, Welch E. T.P.4.01 Identification and characterization of small molecules for the treatment of Duchenne muscular dystrophy Neuromuscular Disorders. 18: 812. DOI: 10.1016/j.nmd.2008.06.301 |
0.085 |
|
| 2006 |
Welch E. The assessment and management of venous thromboembolism. Nursing Standard (Royal College of Nursing (Great Britain) : 1987). 20: 58-64; quiz 66. PMID 16596863 DOI: 10.7748/ns2006.03.20.28.58.c4102 |
0.07 |
|
| 2021 |
Ma J, Risher N, Northcutt V, Moon YC, Weetall M, Welch E, Colacino J, Almstead N, Kong R. Ataluren metabolism: Ataluren-O-1β-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human. Drug Metabolism and Pharmacokinetics. 38: 100393. PMID 33872944 DOI: 10.1016/j.dmpk.2021.100393 |
0.058 |
|
| 2022 |
Welch E, Vaughan J, Cranfield KR, Mehdian R. What implications does the Toombes vs Mitchell case have for other healthcare professionals? Bmj (Clinical Research Ed.). 376: o162. PMID 35058233 DOI: 10.1136/bmj.o162 |
0.053 |
|
| 2005 |
Welch E. Headache. Nursing Standard (Royal College of Nursing (Great Britain) : 1987). 19: 45-52; quiz 54. PMID 15754926 DOI: 10.7748/ns2005.02.19.24.45.c3811 |
0.051 |
|
| 2003 |
Welch E. Hypertension. Nursing Standard (Royal College of Nursing (Great Britain) : 1987). 18: 45-53; quiz 54-5. PMID 14694872 DOI: 10.7748/ns2003.12.18.13.45.c3517 |
0.047 |
|
| 2022 |
Hodes S, Hussain S, Salisbury H, Welch E, Whitaker P. GP crisis requires more than just technology to fix it. Bmj (Clinical Research Ed.). 378: o1670. PMID 35803610 DOI: 10.1136/bmj.o1670 |
0.047 |
|
| 2014 |
Naryshkin N, Dakka A, Gabbeta V, Pichardo J, Woll M, Zhang N, Karp G, Welch E. G.P.104 Neuromuscular Disorders. 24: 826. DOI: 10.1016/j.nmd.2014.06.118 |
0.039 |
|
| 2022 |
Hodes S, Hussain S, Panja A, Welch E, Shire R. When part time means full time: the GP paradox. Bmj (Clinical Research Ed.). 377: o1271. PMID 35595276 DOI: 10.1136/bmj.o1271 |
0.021 |
|
| 2021 |
Sinha A, Abbas G, Ahmad S, Mehta R, Welch E, Bolaji I, Baksi A. Supporting NHS staff facing abuse from patients frustrated by long waits for care. Bmj (Clinical Research Ed.). 375: n2949. PMID 34848494 DOI: 10.1136/bmj.n2949 |
0.019 |
|
| 2011 |
Welch E. Red flags in medical practice. Clinical Medicine (London, England). 11: 251-3. PMID 21902078 DOI: 10.7861/clinmedicine.11-3-251 |
0.011 |
|
| 2022 |
Rhodes F, Basu A, Welch E. Time for change: widening participation in the UKFPO foundation programme. Bmj (Clinical Research Ed.). 376: o715. PMID 35301195 DOI: 10.1136/bmj.o715 |
0.01 |
|
| 2012 |
Welch E, Kwong FN, Mohammed H, Cathcart R. Medical image. An unusual swelling of the forehead. The New Zealand Medical Journal. 125: 88-91. PMID 23178609 |
0.01 |
|
| Hide low-probability matches. |